Form 4: Intra-Cellular Therapies Executive Sanjeev Narula Awarded Restricted Stock Units

Executive Vice President & CFO of Intra-Cellular Therapies, Sanjeev Narula, received 22,727 restricted stock units on February 3, 2025.

Summary

• Sanjeev Narula, Executive Vice President & CFO of Intra-Cellular Therapies, Inc., was granted 22,727 restricted stock units on February 3, 2025.
• These restricted stock units represent a contingent right to receive one share of common stock each.
• The units vest in three equal annual installments, starting on the first anniversary of the grant date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, incentivizing management and aligning interests with shareholders. There are no immediate negative implications.

Positives

• The grant of restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The restricted stock units will vest in three equal annual installments beginning on the first anniversary of the grant date, incentivizing long-term performance.

Industry Context

Stock grants are a common form of executive compensation in the pharmaceutical industry, used to align management interests with shareholder value and incentivize long-term performance.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedule of three years is fairly standard, aligning with industry practices for long-term retention and performance.

Stakeholder Impact

• Shareholders may view the grant positively as it aligns executive interests with long-term company performance.
• Employees may see it as a sign of the company's commitment to its leadership.

Key Dates

Keywords

restricted stock units, Sanjeev Narula, Intra-Cellular Therapies, ITCI, executive compensation, Form 4, stock options, vesting